ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1485

Survivin Measurements Improve Prediction of Rheumatoid Arthritis Among Patients with Unexplained Arthralgia

Malin C Erlandsson1,2, Minna Turkkila3, Rille Pullerits2,3,4 and Maria I Bokarewa2,3, 1Department of rheumatology and inflammation research, University of Gothenburg, Gothenburg, Sweden, 2Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden, 3Department of Rheumatology, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden, 4Department of Clinical immunology and transfusion medicine, Sahlgrenska University Hospital, Gothenburg, Sweden

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: biomarkers and rheumatoid arthritis (RA), Diagnostic Tests, Early Rheumatoid Arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Early recognition of rheumatoid arthritis (RA) is believed to be the key to successful treatment of this disease. Symptoms of arthralgia often predate development of RA. A set of clinical features assisting recognition of patients during their transition from arthralgia to RA, has been recently proposed. We therefore designed a study, in which we followed patients with unexplained arthralgia prospectively aiming to find new cases of RA and to explore a combination of clinical features and serological markers predicting transition from arthralgia to RA. The aim of the present study was to improve recognition of imminent RA among patients with arthralgia (ALG) using a combination of clinical symptoms with RA-specific antibodies RF and anti-CCP and survivin, serological markers predating transition from ALG to RA.

Methods:

All new cases of RA, undifferentiated arthritis (UA) and unexplained ALG were identified among the total of 1743 first-visit patients attending the rheumatology ward in Gothenburg during 12 consecutive months. The ALG patients were prospectively followed for 48 months and development of additional RA cases was recorded. The set of 13 joint symptoms was applied to the first-visit records aiming to distinguish patients with arthritis from ALG and from the new RA cases. The symptoms with odds ratio >2.0 between ALG and pre-RA and information about RF/aCCP and survivin dichotomised were included in predictive models. Receiver operating characteristic (ROC) curves and Kaplan-Meyers curves were constructed.

Results:

Among the first-visit patients, 63 were classified as RA, 73 had undifferentiated arthritis and 180 had ALG. Additional 32 new RA cases developed during 48 months of follow-up and comprised pre-RA group. The analysis of joint symptoms at the first visit distinguished ALG from RA/UA (both, p<0.001). A combination of symptoms in several small joint areas, increasing number of joints with symptoms, and patient’s experience of swelling in small hand joints at the first visit discriminated pre-RA from ALG with 93% sensitivity (p=0.005, AUC=0.660). Presence of survivin in serum strongly associated with 7 of 13, and RF/aCCP with 1 of 13 joint symptoms. Grouping those symptoms with age>50y, gender, survivin and RF/aCCP in the final algorithm allowed reaching 50% sensitivity for transition from ALG to RA (AUC=0.767, p>0.001).

Conclusion:

Clinical and serological parameters in combination aid recognition of imminent RA among ALG patients with appropriate sensitivity.


Disclosure: M. C. Erlandsson, None; M. Turkkila, None; R. Pullerits, None; M. I. Bokarewa, None.

To cite this abstract in AMA style:

Erlandsson MC, Turkkila M, Pullerits R, Bokarewa MI. Survivin Measurements Improve Prediction of Rheumatoid Arthritis Among Patients with Unexplained Arthralgia [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/survivin-measurements-improve-prediction-of-rheumatoid-arthritis-among-patients-with-unexplained-arthralgia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/survivin-measurements-improve-prediction-of-rheumatoid-arthritis-among-patients-with-unexplained-arthralgia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology